山东威高药业股份有限公司

What 山东威高药业股份有限公司 does

Shandong Weigao Pharmaceutical Co., Ltd. (山东威高药业股份有限公司) is a Chinese chemical pharmaceutical manufacturer founded in 2003 and headquartered in the Weihai Torch Hi-Tech Industrial Development Zone, Shandong Province. It is a wholly-owned subsidiary of Weigao Group (威高集团), a diversified Chinese medical products conglomerate, with a registered capital of 66.15 million yuan and 300+ employees. The company develops, produces, and sells pharmaceuticals and medical devices across seven therapeutic categories: nutritional infusions, plasma substitutes, therapeutic infusions, basic infusions, peritoneal dialysis, oral solids, and active pharmaceutical ingredients (APIs). The portfolio spans 20 chemical drug varieties across 35 approval numbers, plus 9 API and packaging material registrations. Notable products include hydroxyethyl starch 130/0.4 sodium chloride injection (plasma volume expander), sorbitol mannitol irrigation solution (urological surgery), amino acid (15) peritoneal dialysis solution, cinacalcet hydrochloride tablets (secondary hyperparathyroidism in CKD), various infusion solutions, loxoprofen sodium capsules, and pre-flush dialyzer/dialysis line flush devices. The company holds GMP, EU CE, and ISO13485 certifications, with manufacturing operations across 40,000+ square meters using 615 sets of modern production equipment.

The company operates a sales-led, field-driven go-to-market model, maintaining direct sales offices in more than 30 provinces and cities across China to serve hospitals and medical institutions. Pricing follows a unit-pricing model with select products reimbursed under China's national medical insurance program (e.g., sorbitol mannitol irrigation solution at 168.16 yuan per 3000ml bag under Category B reimbursement, restricted to transurethral prostate resection and other urological surgical irrigation). The primary customer segments are hospitals, clinics, and healthcare institutions nationwide, with particular therapeutic focus on kidney disease (chronic kidney disease, dialysis, secondary hyperparathyroidism) and perioperative medication fields. The company has partnered with Shenyang Pharmaceutical University for R&D and was recognized as a National New Drug Development Demonstration Enterprise, with a designated Novel Drug Preparation Engineering Technology Center under the Weihai Science and Technology Bureau. Marketing combines direct sales, academic forums, and industry events (e.g., 2020 Liaoning Province endoscopy forum co-hosted with Shenyang Fifth People's Hospital).

A 2020 strategic cooperation agreement with Cytiva (思拓凡), a global biomedical technology provider, established a Phase 2 expansion of bioprocess single-use consumables manufacturing (tripling capacity) targeting China, Japan, South Korea, and global markets. Since October 2024, four products — Amino Acid (15) Peritoneal Dialysis Solution, Cinacalcet Hydrochloride Tablets (the company's first consistency-evaluated product), Sodium Lactate Ringer's Injection, and Sorbitol Mannitol Irrigation Solution — have passed China's generic drug consistency evaluation, marking the company's normalization of bioequivalence work. Recent recognition includes the 2018 National Intellectual Property Advantage Enterprise designation and the 2017 Shandong Province IP Demonstration Enterprise status.

Name

山东威高药业股份有限公司

Legal name

山东威高药业股份有限公司

Website

https://weigaoyaoye.com

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

51–100 employees

Short description

Shandong Weigao Pharmaceutical Co., Ltd. is a Chinese chemical drug manufacturer (founded 2003, Weihai, Shandong) producing 20 pharmaceutical varieties and medical devices. Operating as a subsidiary of Weigao Group, it sells through 30+ provincial offices to hospitals nationwide, focusing on renal and perioperative medications.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Generic Hospital & Institutional Products (HLAIABAL)

Keywords

• Pharmaceutical manufacturing
• Intravenous infusion solutions
• Peritoneal dialysis products
• Generic drug production
• Medical device manufacturing

Headquarters

HQ city

Weihai

HQ country

China

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical products and medical devices sales: The company develops, produces, and sells pharmaceuticals and medical devices, including intravenous solutions, peritoneal dialysis products, oral solid dosages, and active pharmaceutical ingredients. Products are distributed to medical institutions through a nationwide sales network.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

山东威高药业股份有限公司 is a Chinese pharmaceutical manufacturer that develops, produces, and sells chemical drug products and medical devices, organized across seven categories: nutritional infusions, plasma substitutes, therapeutic infusions, basic infusions, peritoneal dialysis solutions, oral solid dosages, and active pharmaceutical ingredients (APIs). The company holds 35 drug approval numbers covering 20 chemical drug varieties plus 9 API and packaging material registrations. Key products include intravenous infusion solutions, peritoneal dialysis solutions, hydroxyethyl starch plasma volume expanders, surgical irrigation solutions, and dialysis circuit flush medical devices, distributed to hospitals and clinics through sales offices in 30+ Chinese provinces and cities.

Product overview

山东威高药业股份有限公司 is a comprehensive pharmaceutical company developing, producing, and selling pharmaceutical products and medical devices. The portfolio includes 20 chemical drug varieties organized into seven pharmaceutical categories (nutritional infusions, plasma substitutes, therapeutic infusions, basic infusions, peritoneal dialysis, oral solids, and active pharmaceutical ingredients) plus medical devices. Key products include Hydroxyethyl Starch Injection for blood volume expansion, Sorbitol Mannitol Irrigation Solution for surgical procedures, Amino Acid Peritoneal Dialysis Solutions for renal care, Cinacalcet Hydrochloride Tablets for hyperparathyroidism, various infusion solutions (glucose, sodium chloride, Ringer's), Loxoprofen Sodium Capsules for pain management, and medical devices including pre-flush dialysis circuit flushers. The company focuses on renal medicine and perioperative medication fields, with recent launches of generic drug consistency evaluated products.

Differentiator

Problem solved

Functional benefit

Products and services

• Hydroxyethyl Starch 130/0.4 Sodium Chloride Injection (羟乙基淀粉130/0.4氯化钠注射液) A plasma volume expander injection (500ml: 50g hydroxyethyl starch 130/0.4 with 4.5g sodium chloride) used for treating and preventing blood volume deficiency in patients evaluated by physicians; cannot substitute red blood cells or coagulation factors. Indicated for hospitals managing hypovolemia, excluding critical care, sepsis, burns, renal impairment, intracranial/cerebral hemorrhage, fluid overload, pulmonary edema, dehydration, severe hypernatremia/hyperchloremia, severe hepatic impairment, congestive heart failure, coagulopathy, and organ transplant recipients.
• Sorbitol Mannitol Irrigation Solution (山梨醇甘露醇冲洗剂) A non-ionic hypotonic irrigation solution (3000ml: 27g sorbitol + 5.4g mannitol per 1000ml) for transurethral prostate resection and other urological surgical irrigation. Provides clear surgical field of view, suitable for diabetic patients (non-conductive, sugar-free), with diuretic effect and ability to soften blood clots for instrument cleaning. Reimbursed under Chinese medical insurance category B at 168.16 yuan per 3000ml bag; limited to transurethral prostate resection and intraoperative urological surgical irrigation.
• Cinacalcet Hydrochloride Tablets (盐酸西那卡塞片) 25mg oral tablet for treating secondary hyperparathyroidism in chronic kidney disease (CKD) patients on maintenance dialysis. Initial adult dose: 25mg once daily with meals; titratable up to 75mg daily based on iPTH, serum calcium, and serum phosphorus, with maximum 100mg daily. Reimbursed under Chinese medical insurance category B.
• Amino Acid (15) Peritoneal Dialysis Solution (氨基酸(15)腹膜透析液) Glucose-free peritoneal dialysis solution used as part of peritoneal dialysis regimens for chronic kidney failure patients, particularly suitable for those with serum protein below 35g/L. Indicated for hospital peritoneal dialysis programs.
• Plastic Bottle Infusion Products (塑料瓶输液产品) Plastic bottle packaged infusion solutions for hospital IV therapy, including 5% and 10% glucose injections, 0.9% sodium chloride injection, glucose-sodium chloride injection, compound sodium chloride injection, sodium lactate Ringer's injection, mannitol injection, and normal saline in multiple specifications.
• Soft Bag Infusion Products (软袋输液产品) Flexible container (soft bag) infusion solutions for basic IV therapy in clinical settings, offered as an alternative packaging format to plastic bottles.
• Calcium Carbonate D3 Chewable Tablets (碳酸钙D3咀嚼片) Chewable calcium supplement tablets containing 500mg calcium and 200IU vitamin D3 per tablet for children, pregnant and lactating women, menopausal women, and the elderly to prevent and treat osteoporosis.
• Loxoprofen Sodium Capsules (洛索洛芬钠胶囊)
• Medium and Long Chain Fat Emulsion Injection (C8~24) (中/长链脂肪乳(C8~24)注射液) Parenteral nutrition injection containing soybean oil and medium chain triglycerides, providing energy and essential fatty acids for patients unable to receive adequate oral or enteral nutrition.
• Xylitol Injection (木糖醇注射液) 250ml:25g sugar-substitute injection for intravenous infusion in diabetic patients requiring energy supply without glucose.
• Compound Amino Acid (15) Dipeptide (2) Injection (复方氨基酸(15)双肽(2)注射液) 500ml:67g parenteral nutrition injection for patients unable to take oral or enteral nutrition, especially indicated for moderate to severe catabolic conditions.
• Acetylglutamine Sodium Chloride Injection (乙酰谷酰胺氯化钠注射液) 250ml:0.25g therapeutic injection indicated for traumatic coma, neurosurgery coma, hepatic coma, hemiplegia, high paraplegia, polio sequelae, nervous headache and waist pain.
• Levofloxacin Lactate Sodium Chloride Injection (乳酸左氧氟沙星氯化钠注射液) 100ml:0.2g fluoroquinolone antibiotic injection for respiratory, urinary, reproductive, skin, soft tissue, and other moderate to severe bacterial infections.
• Diacetylaminoethyl Ethylenediamine Sodium Chloride Injection (二乙酰氨乙酸乙二胺氯化钠注射液) 250ml:0.6g hemostatic injection for preventing and treating bleeding from surgery, trauma, respiratory, ENT, gynecological, hemorrhoidal, urinary, digestive, and intracranial hemorrhage.
• Piracetam Sodium Chloride Injection (吡拉西坦氯化钠注射液) Nootropic injection (50ml:10g and 100ml:20g formulations) for treating intracranial pressure increase caused by brain trauma.
• Fasudil Hydrochloride Injection (盐酸法舒地尔注射液) 2ml:30mg vasodilator injection for improving and preventing cerebral vasospasm and cerebral ischemia symptoms after subarachnoid hemorrhage surgery.
• Sodium Lactate Ringer's Injection (乳酸钠林格注射液)

Quantifiable outcome

• 4 products passed bioequivalence evaluation (一致性评价) since 2024, indicating standardized generic drug development capability

Named customers5 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• Cytiva (思拓凡)coreStrategic or Co-development Partner · 6 November 2020Weigao Pharmaceutical Industrial Group entered into a strategic cooperation agreement with Cytiva (思拓凡), a global technology and service provider for biomedical R&D and production, during the 2020 China International Import Expo (CIIE) in Shanghai. The partnership involves a second-phase expansion of bioprocess single-use consumables manufacturing, including single-use mixing bags, storage bags, bioreactor bags, components, and customized products. The expanded Phase 2 project triples production capacity, serving markets in China, Japan, South Korea, and globally.

Scale indicators6 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• B. Braun: Global medical technology company with strong focus on IV solutions, infusion systems, clinical nutrition, and dialysis-related medical devices. Comparable to Weigao Pharmaceutical in IV infusion, parenteral nutrition, and dialysis-related portfolios serving hospitals.
• Kelun Pharmaceutical (科伦药业): China's largest large-volume parenteral (LVP) infusion manufacturer, producing basic IV solutions, parenteral nutrition, and generic injectables for hospital sale. Directly comparable to Weigao Pharmaceutical across basic/therapeutic infusions and generic injectables in the Chinese hospital channel.
• Fresenius Kabi: Global leader in clinical nutrition, IV infusion solutions, and medical devices for fluid/blood administration. Comparable to Weigao Pharmaceutical in parenteral nutrition (medium/long-chain fat emulsion, amino acid injections), basic IVs, and renal/dialysis adjacencies.
• Baxter International: Global leader in peritoneal dialysis solutions and hospital IV therapies. Direct overlap with Weigao Pharmaceutical across Amino Acid Peritoneal Dialysis Solution and clinical IV solutions serving renal and surgical patients.
• Cisen Pharmaceutical (辰欣药业): Chinese pharma company specializing in LVP basic IV infusions, therapeutic injections, and oral solid generics. Comparable product mix (basic IV, nutrition) and target buyers (medical institutions) to Weigao Pharmaceutical.
• China Resources Double-Crane Pharmaceutical (华润双鹤药业): Major Chinese generic pharma manufacturer with a leading share in large-volume IV infusions (basic, nutrition, therapeutic) and oral solid generics. Closely mirrors Weigao Pharmaceutical in product portfolio and Chinese hospital-segment GTM.

Broad incumbents

• Shanghai Pharmaceuticals Holding: One of China's largest pharmaceutical conglomerates, spanning manufacturing and distribution of pharmaceuticals and consumer health. Touches Weigao Pharmaceutical's product categories (generic IV, oral solids, APIs) at much greater scale and breadth.
• CSPC Pharmaceutical Group (石药集团): Major Hong Kong-listed Chinese pharma conglomerate spanning generic drugs and innovative drugs, including IV formulations and oral solids. Overlaps Weigao Pharmaceutical's categories but operates at substantially broader scope and larger scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/%E5%B1%B1%E4%B8%9C%E5%A8%81%E9%AB%98%E8%8D%AF%E4%B8%9A%E8%82%A1%E4%BB%BD%E6%9C%89%E9%99%90%E5%85%AC%E5%8F%B8

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about 山东威高药业股份有限公司